<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thrombopoietin (TPO), a major cytokine involved in megakaryocytopoiesis/thrombopoiesis, may be effective for treatment of the <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> associated with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, it has been unclear whether TPO stimulates proliferation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> blasts, as observed in de novo <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This study examined this concern </plain></SENT>
<SENT sid="3" pm="."><plain>When marrow cells from 37 MDS cases were cultured with or without recombinant human PEGylated TPO, TPO increased the blast number (stimulation index &gt; or =1.5) in 9 of 16 high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>] and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation) and 4 of 10 cases with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transformed to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-AL), but none of 11 cases with low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (RA and RA with ringed sideroblasts) </plain></SENT>
<SENT sid="4" pm="."><plain>When the cell cycle of cultured cells was determined by three-color flow cytometry, TPO activated the cell cycle of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cells (causing a decrease in G(0)-phase cells) in most of the cases whose blast number increased in response to TPO </plain></SENT>
<SENT sid="5" pm="."><plain>Reverse transcriptase-polymerase chain reaction analysis detected TPO receptor <z:chebi fb="5" ids="33699">messenger RNA</z:chebi> in purified blasts from <z:hpo ids='HP_0000001'>all</z:hpo> six cases examined, irrespective of the response of their blasts to TPO in culture </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of the patients' characteristics identified a high-serum <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) value as being associated with blast proliferation in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases (p = 0.0036) </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that TPO stimulates in vitro proliferation of blasts from a fraction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>High-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, especially those who have a high-serum LDH value, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-AL patients should be monitored with particular care in clinical trials of TPO for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>